Introduction
It is well established that cortisol is a useful index for monitoring pituitary gland and adrenal functions and diagnosing adrenocortical diseases including Cushing's syndrome. Thus, development of practical immunoassays of this steroid has been an important subject in biomedical analytical chemistry. The specificity of antibodies against haptens such as steroids is significantly influenced by the position on the hapten molecule used for conjugation with a carrier protein to yield an immunogen. Various kinds of antisera against cortisol have been generated so far using the C-3, C-6, C-7, or C-21 position on the steroid nucleus for the conjugation. 1 Some of these antisera provided practical radioimmunoassay (RIA) systems but were not always available for developing enzyme immunoassay (EIA) systems. On the other hand, Hosoda et al. found that the C-4 position on 4-en-3-one type steroids such as cortisol is suitable for the conjugation not only to produce specific antibodies but also to construct sensitive bridge heterologous EIA systems. [1] [2] [3] [4] [5] [6] [7] The latter advantage is due to the fact that various types of chemical bridges can be introduced to the C-4 position via a 4,5-epoxide as a key intermediate. 8, 9 Indeed, reasonably specific polyclonal antibodies have been prepared against cortisol 1 and 11-deoxycortisol 4 using corresponding haptenic derivatives having a chemical bridge at their C-4 position. These antibodies were also useful for developing EIA systems providing practical sensitivity and specificity. 3, 6 Modern immunoassays require the use of monoclonal antibodies, which are obtainable by the hybridoma technology. 10 These antibodies can be supplied constantly maintaining welldefined and unique binding properties and consequently allow us to standardize assay performance. From these points of view, a few studies have been done so far to generate monoclonal anti-cortisol antibodies. In these studies, mice were immunized with a cortisol derivative linked to bovine serum albumin (BSA) via the C-3 position to afford immune spleen cells for the fusion experiment. 11, 12 However, the resulting antibodies did not afford truly excellent immunoassay systems showing high sensitivity and specificity.
In this study, we investigated the generation of a monoclonal antibody showing improved affinity and specificity for cortisol using a cortisol- Measurement of cortisol levels in body fluids is important for monitoring pituitary gland and adrenal functions. To develop a specific and standardized enzyme-linked immunosorbent assay (ELISA), a novel monoclonal anti-cortisol antibody has been generated using a reasonably designed haptenic derivative. Spleen cells were prepared from the BALB/c or A/J mouse, which had repeatedly been immunized with a conjugate of 4-(2-carboxyethylthio)cortisol (CET) and bovine serum albumin, to be fused with P3/NS1/1-Ag4-1 myeloma cells. After four fusion experiments, one hybridoma clone secreting a practical antibody has been established. The resulting monoclonal antibody CS#38 (isotype γ1, κ) showed an affinity constant (Ka) for cortisol of 1 × 10 9 M -1 and provided a practical calibration curve (detection limit, 0.26 ng per assay) in a homologous ELISA system employing horseradish peroxidase-labeled CET as a labeled antigen. Cross-reactivities with related C-21 steroids were acceptably low: 11-deoxycortisol (4.3%), cortisone (4.0%), corticosterone (1.9%), progesterone (1.6%), 17α-hydroxyprogesterone (12%), 6β-hydroxycortisol (8.4%), and tetrahydrocortisol (<0.1%). Urinary and serum cortisol levels of healthy volunteers were determined by this method after methylene chloride extraction to be 39.0 ± 17.0 µg/day (n = 7) and 80.8 ± 38.9 ng/mL (n = 10), respectively, both of which are in the reference range.
several murine strains. One of the resulting antibodies was equipped with suitable binding properties to develop an ELISA system to determine human urinary and serum cortisol levels.
Experimental

Materials
Tetrahydrocortisol (3α,5β-isomer) and 6β-hydroxycortisol were purchased from Steraloids, Inc. (Newport, RI, USA). Other unlabeled steroids and BSA were obtained from Sigma Chemical Co. (St. Louis, MO, USA). [1,2,6,7-3 H]-cortisol (1.74 TBq/mmol) was purchased from Amersham Pharmacia Biotech (Buckinghamshire, England). The haptenic derivative, 4-(2-carboxyethylthio)cortisol (CET) and its N-succinimidyl ester ( Fig. 1) were synthesized according to the previously reported method. 1, 8 Horseradish peroxidase (HRP; EC 1.11.1.7, grade I-C) (263 U/mg) was obtained from Toyobo Co. (Osaka, Japan). Freund's complete adjuvant (FCA) and incomplete adjuvant (FIA) were purchased from DIFCO (Detroit, MI, USA). AffiniPure rabbit anti-mouse IgG + IgM antibody (the second antibody in the following ELISA) was obtained from Jackson ImmunoResearch (West Grove, PA, USA). 96-Well EIA/RIA plates (No. 3590) and plastic cell culture wares were purchased from Costar (Cambridge, MA, USA). Reagents for cell culture including media, fetal bovine serum, hybridoma cloning factor (HCF) and polyethylene glycol (PEG) were those previously described. 13, 14 All other reagents and solvents were of analytical grade.
Buffers
Buffer A, 0.05 M sodium phosphate buffer (pH 7.3); buffer B, buffer A containing 0.1% gelatin and 0.9% NaCl; buffer C, buffer A containing 0.9% NaCl; buffer D, buffer C containing 0.05% (v/v) Tween 20.
Preparation of hapten-carrier conjugates
The hapten-carrier conjugate for immunization was prepared by the reaction between the N-succinimidyl ester of CET (ca. 40 mol equiv. to BSA) and BSA. 1 The hapten/BSA molar ratio of the resulting conjugate was determined to be 27 from UV absorption at 250 nm on the assumption that the molar extinction coefficient of the hapten is 11000. 1 
Preparation of enzyme-labeled antigen
The N-succinimidyl ester of CET was reacted with HRP (2.0 mg) in buffer A/dioxane (2:1; 300 µL) at 4˚C for 4 h. 15 The molar ratio of the activated ester to the enzyme in this reaction was adjusted to 10. Unreacted steroids were thoroughly removed by dialysis (against cold buffer A for 2 d) and subsequent extraction with CHCl3. The resulting solution of enzyme-labeled cortisol was diluted with buffer B and stored at 4˚C until use.
Immunization
Female BALB/c, A/J, C57/BL6 mice, and SD (Sprague Dawley) rats (each 6 -8 weeks of age; each 5 heads) (Japan SLC; Hamamatsu, Japan) were immunized biweekly with the hapten-carrier conjugate.
The conjugate (50 µg) was subcutaneously injected with an emulsion of FCA (primary immunization) or FIA (booster immunizations) and sterile saline (1:1; 0.2 mL), into the footpads and at multiple sites on the back. Seven days after the sixth booster injection, blood was collected and the binding ability of the serum antibodies to cortisol was determined by the ELISA procedure (see below). The conjugate (50 µg) in a sterile saline (0.2 mL) was intraperitoneally injected into the two BALB/c mice and two A/J mice that showed a relatively high immune response, from which spleen cells were prepared 3 days later.
Monoclonal antibody production
The cell fusion experiment was performed according to our previous papers. 13, 14 Briefly, the immune spleen cells (1 × 10 8 cells) and 1/5 numbers of P3/NS1/1-Ag4-1 myeloma cells 16 were fused with 40% PEG 4000 in a sterile phosphate-buffered saline containing 10% DMSO and 0.001% poly-L-arginine·HCl solution (1 mL). The fused cells were suspended in an HAT medium supplemented with 10% HCF and cultured in 96-well cluster dishes (100 µL/well) overnight under 5% CO2-95% air at 37˚C. After further culture for approximately two weeks in HAT medium, the hybridoma supernatants were submitted to screening by the ELISA described below. The antibodysecreting hybridomas were expanded in HT medium, cloned by limiting dilution, and were grown until confluence was reached. The resulting supernatant was used for characterization of the monoclonal antibody contained therein.
ELISA
A solution of the second antibody diluted at 1:400 with buffer A (100 µL) was distributed into each well of the EIA/RIA plates, which were left overnight at 4˚C. After washing 3 times with buffer C, the wells were blocked with a 5% skimmed milk solution in buffer C (300 µL) at 37˚C for 1 h. The wells were washed 3 times with buffer D, to which hybridoma supernatants or monoclonal antibody solutions suitably diluted with buffer B (100 µL) were then added.
After incubation at room temperature for 1 h, the solutions were aspirated off and the wells were washed 3 times with buffer D. The HRP-labeled cortisol (25 ng) dissolved in buffer B (100 µL) and standard cortisol (or an analog) diluted with 20% ethanol (25 µL) were then added, mixed and incubated at room temperature for 3 h. After washing in the same manner, the bound enzyme activity on the plate was colorimetrically measured using a substrate solution (100 µL) containing 0.04% o-phenylenediamine·2HCl and 0.018% H2O2. After incubation at room temperature for 30 min, the enzymic reaction was terminated by the addition of 1 M H2SO4 (100 µL). The absorbance at 492 nm was measured using a MPR A4i microplate reader (Tosoh; Tokyo, Japan).
Pretreatment of human urine and serum samples for ELISA a) Urine samples. The [ at room temperature for 1 h, which was then extracted with CH2Cl2 (4.0 mL) by double vortex-mixing (each 20 s). After centrifugation at 2800 rpm for 15 min, the organic layer (3.0 mL) was transferred to a counting vial and evaporated. The residue was dissolved in 20% ethanol (375 µL), and a portion (75 µL) was used as an ELISA sample. A scintillation cocktail (10 mL) was added to the remaining solution (300 µL) to count radioactivity. b) Serum samples. The [ 3 H]-cortisol (40 Bq) in ethanol (50 µL) was placed into a tube. After evaporation of the solvent, a serum specimen (500 µL) and saline (500 µL) were added, mixed and allowed to stand at room temperature for 1 h. The sample was extracted with CH2Cl2 (2.0 mL) in the same manner described above. The organic layer (1.5 mL) was transferred to a counting vial and evaporated. The residue was dissolved in 20% ethanol (375 µL) and a portion (75 µL) was used as an ELISA sample. A scintillation cocktail (10 mL) was added to the remaining solution (300 µL) to count radioactivity.
Analytical recovery test
The [ 3 H]-cortisol (70 Bq) and standard cortisol (0, 40, 80, or 120 ng) (both in ethanol; 50 µL) were mixed with a charcoaltreated urine sample (2.0 mL), allowed to stand at room temperature for 1 h, and then extracted with CH2Cl2 (4.0 mL) as above. This procedure was performed in duplicate for each dose of cortisol. The organic layers from the same dose (3 mL × 2) were combined in a counting vial, and the solvent was evaporated. The residue was dissolved in 20% ethanol (750 µL), and an aliquot (450 µL) was used for ELISA.
Radioactivity was counted using the remaining solution (300 µL).
Results
Production of monoclonal antibodies
Although BALB/c mice are the commonest spleen donor in the cell fusion experiments, we previously encountered the cases where A/J mice showed obviously better immune response to some steroid haptens. 13, 17 Considering these results, we immunized both BALB/c and A/J mice simultaneously with the immunogen, the BSA conjugate of the haptenic derivative CET (Fig. 1) . C57/BL6 mice 18, 19 and SD rats 20 were also immunized with the same immunogen, considering previous reports using these strains for successful production of monoclonal anti-steroid antibodies. However, no significant difference in the response was observed between these strains, and we selected two BALB/c mice and two A/J mice that showed a relatively high immune response as spleen donors. Four fusion experiments were carried out using the spleen cells from one of the selected mice. After the HAT-selection, hybridomas were observed in almost all the microcultures (totally, 1896 wells were used), among which 4 hybridoma cultures were found to be secreting an antibody which strongly binds to HRP-labeled cortisol in the ELISA. These hybridomas were cloned and grown as described above, and 4 corresponding kinds of monoclonal antibodies (CS#2, CS#5, CS#34, and CS#38) were obtained as the culture supernatant.
Characterization of monoclonal antibodies
Isotypes of heavy and light chains of the monoclonal antibodies were γ1 and κ (CS#5 and CS#38) or γ 2a and κ (CS#2 and CS#34). The binding characteristics of the antibody were investigated by the ELISA using an HRP-labeled CET as a labeled antigen. The optimum dilution of the antibody (culture supernatant) was arbitrarily determined to be 1:3000, 1:4000, 1:3000, and 1:800 for CS#2, CS#5, CS#34, and CS#38, respectively, at which the enzyme activity of B0 corresponds to approximately 0.5 absorption unit (30 min incubation). The absorption due to nonspecific binding in the absence of antibody was below 5% of the B0 value.
The four antibodies all provided dose-response curves for cortisol with a practical measurable range even in the homologous combination using the enzyme-labeled CET (Fig.  2A) . The specificity of these antibodies was examined by a 1311 ANALYTICAL SCIENCES DECEMBER 2002, VOL. 18 A B cross-reaction study 21 with seven related compounds, taking the reactivity of cortisol as 100% ( Table 1 ). The antibody CS#38 showed obviously better specificity than the other antibodies from the viewpoint of clinical application. Namely, this antibody afforded much lower cross-reactivities with 11-deoxycortisol and cortisone, both of which have a very similar chemical structure to cortisol and could potentially interfere with determination of serum/plasma cortisol levels in some cases. Cross-reactivities with the other analogs were similar or lower than those of an EIA system that Hosoda et al. previously established using a polyclonal antibody elicited with the same immunogen ( Table 1) . 3 However, cross-reactivity with 6β-hydroxycortisol, which is one of the major urinary metabolites of cortisol, 22 was significantly higher. Thus, we next examined the specificity from the viewpoint of applicability to urine specimens. Urine was collected from two healthy men (both 43 years old) for 24 h and submitted to the four ELISA systems each using one of the monoclonal antibodies (Fig. 3A) . Although direct measurement afforded obviously overestimated assay values (data not shown), we could obtain acceptable assay values by employing methylene chloride extraction as a pretreatment.
Among the four antibodies, CS#38 showed the lowest assay values for both urine specimens, consistent with the cross-reactivity, and consequently, this antibody was determined to possess the most suitable properties for practical use.
The dose-response curve of this ELISA using the antibody CS#38 was separately obtained taking the standard variation (SD) at each dose (Fig. 2B) . The detection limit, defined as the amount of cortisol required to give a B/B0 of 2SD below, was 0.26 ng per assay. The affinity constant of the antibody CS#38 for cortisol was determined to be 1 × 10 9 M -1 by Scatchard analysis using the [ 3 H]-cortisol. 23 
Clinical application of ELISA
We examined the clinical application of the ELISA system using the antibody CS#38. Urinary free cortisol levels are a useful index in clinical diagnosis. However, its measurement is often accompanied by overestimation due to various kinds of metabolites having similar structures and coexisting in excess amounts and is thus more difficult than measurement of serum/plasma levels. Considering this, we first attempted to measure the urinary levels and found that a single extraction with methylene chloride permits reasonable assay values as described above.
The mean recovery rate through this extraction was determined using the [ 3 H]-cortisol as a tracer to be 85 ± 5.8 (SD) % (n = 7). Acceptable parallelism was observed between the assay values and the dilution ratio of urine specimens as shown in Fig. 3B . Analytical recovery rates were 98.4 and 108%, when charcoal-stripped urine specimens were measured after the addition of known amounts of standard cortisol (0.5 and 1.5 ng/assay, respectively). The coefficients of variation of the intra-assay (4.4%, mean 1.90 ng/assay; n = 6) and inter-assay (8.1%, mean 1.98 ng/assay; n = 6) variance, determined for the measurement of that spiked sample (1.5 ng/assay) were in acceptable range. The mean daily excretion rate of free cortisol, determined for 7 healthy male volunteers (age: 22 -43 years old), was 39.0 ± 17.0 (SD) µg/day. This ELISA also provided reasonable cortisol levels for serum samples by employing methylene chloride extraction: the mean extraction rate was 81 ± 7.7 (SD) % (n = 10). The mean serum level of 10 healthy volunteers (5 males and 5 females) (age: 19 -27 years old) was 80.8 ± 38.9 (SD) ng/ml.
Both the urinary and serum cortisol levels obtained here were in the reference range and were compatible with previously reported data determined using various analytical methods ( Table 2 ).
Discussion
Because of the well-established utility of cortisol as a diagnostic index, generating a monoclonal anti-cortisol antibody that is available for use in immunoassay systems is still important. However, to our knowledge, only two papers have officially been published dealing with this subject. 11, 12 The earlier study 11 produced several antibodies showing low cross-reaction with 11-deoxycortisol after various trials for immunization using cortisol 3-(O-carboxymethyl)oxime (3-CMO) as the haptenic derivative. These attempts involved the use of neonatally tolerized mice against cross-reacting steroids. Some antibodies obtained here showed excellent sensitivity in an RIA system but have not been applied to clinical samples. The latter study 12 produced some antibodies after immunization with the 21- Serial dilution study for the ELISA using antibody CS#38. Methylene chloride extract of urine sample was prepared as described in Experimental (corresponds to ×1 sample), and then serially diluted twofold with 20% ethanol to prepare ×2 and ×4 samples, each of which was submitted to the ELISA.
acetate of 3-CMO conjugated with BSA. One of the antibodies was applied to ELISA for determining plasma cortisol levels but exhibited somewhat poor sensitivity (we estimated this to be ca. 1 ng/assay based on the reported dose-response curve) as well as significant cross-reaction with 11-deoxycortisol (19%) . Although this ELISA enabled direct measurement of the plasma levels using stripped human plasma for calibration, it has not been applied to urine specimens. Using a well-designed haptenic derivative, exposing characteristic functional groups on the target hapten outside of the carrier protein, is important to generate specific antibodies against haptens. In addition, selecting a suitable murine strain showing a strong humoral immune response against such a haptenic derivative is required. Taking these factors into account, we immunized various murine strains with the cortisol-[C-4]-BSA conjugate. However, we could not find a strain exhibiting obviously better response when we checked the titer of antibodies in serum after the sixth booster immunization. Moreover, these serum antibodies all exhibited dose-response curves for cortisol with poor sensitivity (ng-µg range), and significant cross-reaction with 11-deoxycortisol (over 40%). These results suggested that production of a specific monoclonal anti-cortisol antibody by the cell fusion technique might be much more difficult compared with other steroid antigens that we had dealt with so far (e.g., bile acid conjugates, 13, 14 1α,25-dihydroxyvitamin D3, 17, 20 and 11-deoxycortisol). 24 It would be conceivable that these murine strains tested here scarcely possess such B-cell clones that are equipped with surface receptors showing high specificity and affinity for cortisol.
After repeating four fusion experiments, from among over a thousand hybridoma microcultures, we obtained a hybridoma clone secreting the anti-cortisol antibody CS#38 showing practical binding properties in the homologous ELISA system. The urinary and serum cortisol levels obtained for healthy volunteers were in the reference range (Table 2) , which results strongly suggested that the present ELISA is valid for clinical application. Because the recovery rates of cortisol from these body fluids were satisfactorily high and reproducible, the use of the tritium-labeled compound could be omitted for routine analysis. We are now further investigating application of the ELISA to various clinical samples. It should be noted that the bridge heterologous ELISA system combining the antibody CS#38 and a different HRP-labeled antigen, the conjugate of 4-carboxymethylthiocortisol 1, 8 and HRP, having a shorter bridge than the CET derivative, did not show improved assay sensitivity. 5, 7 This fact suggests that the antibody CS#38 would not recognize the bridge portion linking the cortisol moiety to BSA or HRP.
It would be challenging to create a mutant antibody fragment (e.g., a single-chain Fv fragment; scFv) against cortisol having much more improved affinity (e.g., Ka > 10 10 M -1 ) and specificity than those of hybridoma-based antibodies, by manipulation of the genes encoding variable regions (V-genes) 25 of the antibody CS#38. Cloning of these V-genes and assembling them to produce a wild-type scFv derived from CS#38 is also ongoing in our laboratory. 
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